At the beginning of 2026, China’s oncology treatment field has achieved a major breakthrough. On January 5, the China National Medical Products Administration (NMPA) officially approved the new-generation targeted drug Repotrectinib for the treatment of adult patients with solid tumors harboring neurotrophic tyrosine receptor kinase (NTRK) gene fusions. This approval brings new hope and options to many advanced solid tumor patients facing treatment challenges, especially those who have failed prior therapies or lack effective treatment options.
**About Ocapler® (Repotrectinib): A New-Generation, Potent, and Precise Targeted Drug**
Ocapler® (Repotrectinib) is a new-generation tyrosine kinase inhibitor (TKI) uniquely designed to precisely target ROS1 and NTRK oncogenic gene fusions. For patients with solid tumors (including non-small cell lung cancer, etc.) carrying these genetic alterations, Repotrectinib demonstrates significant efficacy even after resistance to prior targeted therapies. It also effectively controls brain metastases, providing more durable treatment benefits.
**Solid Data Showcasing Outstanding Efficacy**
The NMPA’s approval is based on the global Phase 1/2 TRIDENT-1 pivotal study. The results are encouraging:
- **For patients previously treated with TRK-targeted therapy:** The objective response rate (ORR) reached 50%, with a disease control rate (DCR) of 42%.
- **For treatment-naïve patients not previously treated with TRK-targeted therapy:** The efficacy is even more remarkable, with an objective response rate as high as 58%, including a complete response (CR) rate of 15%, meaning tumors completely disappeared in some patients. Notably, 83% of responders continued to benefit one year later.
These data clearly demonstrate Repotrectinib’s potent and durable anti-tumor activity, along with a manageable safety profile, in patients with NTRK fusion-positive solid tumors.
**Beijing South Region Oncology Hospital International Department: Your Gateway to Global Healthcare**
As one of China’s leading oncology diagnosis and treatment centers, Beijing South Region Oncology Hospital International Department is always at the forefront of the fight against cancer. The International Medical Department is our dedicated window for patients from around the world, committed to providing high-quality, personalized medical services that align with international standards.
**Why Choose Us?**
1. **Access to Global Cutting-Edge Therapies:** We closely follow the latest global drug approvals (such as the recent approval of Repotrectinib), ensuring international patients can access advanced treatment options in China that are synchronized with those available in the United States, Europe, and other regions.
2. **Multidisciplinary Expert Team (MDT):** We have an experienced expert team in various solid tumor fields, including lung cancer, sarcoma, and thyroid cancer, capable of providing precise diagnosis and comprehensive treatment planning for patients with rare gene fusions such as NTRK.
3. **One-Stop International Patient Services:** From initial consultation, medical record review, appointment scheduling, and expert consultations to treatment arrangements, hospitalization support, and follow-up care, we offer seamless, multilingual, and attentive services throughout the entire process.
4. **Convenient Cross-Border Medical Coordination:** We deeply understand the travel and communication needs of international patients and can provide necessary assistance to ensure your medical journey is smooth and worry-free.
**Contact Us Now to Begin Your Precision Treatment Journey**
If you or your loved ones are seeking new hope for the treatment of NTRK fusion-positive solid tumors, please contact us immediately. Our International Medical Department’s professional team is ready to assess your eligibility and provide detailed medical guidance.
- **International Patient Hotline:** 400-880-3716
- **WeChat/WhatsApp:** +86 17801183037 (WeChat ID: 17801183037)
- **Email:**
100085_010@163.com
myimmnet@163.com
*(Please note: To ensure communication efficiency, when sending medical records, kindly copy both email addresses and include a brief description of the condition.)*
**Action Tip:**
Please prepare relevant pathological reports, genetic test reports (especially those containing NTRK gene fusion results), and prior treatment records to provide when contacting us. This will help our experts conduct a rapid and accurate preliminary assessment.
Beijing South Region Oncology Hospital International Department is committed to safeguarding the health and lives of patients worldwide with professional medical expertise and warm, compassionate care. We look forward to your inquiry
Post time: Jan-08-2026